For research and educational purposes only. Not medical advice.

KLOW Reference

Educational, not medical advice reference for KLOW: Recovery, Skin/Hair, Immune; regulatory status, evidence posture, source review, and schedul…

Plain English

What it is
KLOW is a nickname for a mixed peptide product, not a single approved drug. It is the GLOW blend with one more peptide added, so it holds four lab-made peptides in one vial: GHK-Cu, BPC-157, TB-500, and KPV. It is sold for research and is not an approved medicine.
What people use it for
People use KLOW for the same goals as GLOW (nicer skin and hair, plus tendon and joint recovery), with the extra KPV part aimed at calming inflammation and gut irritation. This comes from personal stories in peptide communities, not from approved medical directions.
What the science shows
No study has ever tested these four peptides together, so the blend is unproven. On their own, GHK-Cu is best supported in skin creams, BPC-157 and TB-500 come mostly from animal studies, and KPV has been tested mainly in animal models of gut and skin inflammation. Strong human proof is missing across the board.
The catch
Nothing here is FDA-approved. BPC-157, TB-500, and KPV are all flagged in FDA reviews of pharmacy-compounded peptides, and BPC-157 is banned for athletes. Because GHK-Cu carries copper, it can be risky for people with copper-handling problems such as Wilson's disease or a copper allergy. Mixed research vials also have no quality checks, so what is actually inside can vary.

Reference summary

There are no published studies of KLOW as a combination; all evidence is per ingredient and does not test the four peptides together. GHK-Cu has the strongest support in topical and ex vivo human-skin and animal wound studies, not injectable human trials. BPC-157 is dominated by preclinical rodent injury studies with only a handful of small human pilot reports. TB-500 evidence is largely extrapolated from full-length thymosin beta-4 animal work. KPV is studied mostly in rodent colitis and dermatitis models via PepT1-mediated uptake, with limited direct human evidence.

Regulatory and posture

Categories
Recovery, Skin/Hair, Immune
Aliases
KLOW, KLOW blend, KLOW peptide blend, GLOW plus KPV, GHK-Cu + BPC-157 + TB-500 + KPV
Evidence posture
preclinical - No studies test KLOW as a blend. Per-ingredient evidence is thin: GHK-Cu is strongest topically, BPC-157 and TB-500 are mostly animal data, and KPV is mostly rodent inflammation models.
Regulatory status
No FDA-approved drug label exists for the KLOW blend or for its individual ingredients. KLOW is a community name for a research-only combination that adds KPV to the GLOW blend, pairing GHK-Cu, BPC-157, and TB-500 with KPV; the blend itself has never been reviewed or approved by any regulator. FDA placed BPC-157 (acetate and arginate salt forms) in Category 2 of the 503A interim bulk drug substances list on September 29, 2023, meaning it is not permitted for section 503A pharmacy compounding. On April 16, 2026, FDA published a Federal Register notice (docket FDA-2025-N-6895) scheduling a Pharmacy Compounding Advisory Committee meeting for July 23-24, 2026 to consider BPC-157, TB-500, and KPV, along with MOTS-c, for the 503A Bulks List; pending that review none of the three is permitted for 503A compounding. BPC-157 is prohibited for athletes under the WADA S0 non-approved substances category. GHK-Cu is sold as a low-concentration cosmetic ingredient, but that cosmetic posture does not transfer to injectable use.
Content review status
research reference

Selected public sources

Related tools